Cardio Diagnostics, Aimil, and Dr. Lal PathLabs Collaborate on Coronary Heart Disease Test

Cardio Diagnostics Holdings Inc., Aimil Ltd., and Dr. Lal PathLabs have announced a strategic agreement to launch Cardio Diagnostics’ PrecisionCHD test for detecting and managing coronary heart disease (CHD) in India.

This partnership marks Cardio Diagnostics’ first expansion outside the United States and official entry into the Indian market. It also represents a major step toward making Cardio Diagnostics’ advanced technology accessible in India, where cardiovascular disease remains a leading and growing health concern. The prevalence of CHD in India varies by population settings, with a prevalence of up to 7.4% and 13% reported in rural and urban areas, respectively.

“We are thrilled to partner with Aimil and Dr. Lal PathLabs to bring PrecisionCHD to India,” Cardio Diagnostics Co-Founder/CEO Dr. Meesha Dogan said. “This partnership is a major step forward in democratizing access to advanced cardiovascular diagnostics and is a result of our ongoing effort to expand the reach of our technology beyond the U.S. market.”

PrecisionCHD is a clinical blood test that can detect CHD at a molecular level by combining epigenetics and genetics with AI technology. This clinically validated test delivers actionable insights that can help physicians understand the key molecular drivers of disease, crucial for personalized treatment, as well as ongoing management. In addition to detecting obstructive CHD—which angiograms can also detect—the PrecisionCHD test can detect non-obstructive CHD, which angiograms typically cannot pick up. Data supporting PrecisionCHD’s ability to detect Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA), which are two common forms of non-obstructive disease, were presented earlier this month at the American Heart Association Scientific Sessions held in New Orleans.

“Partnering with Cardio Diagnostics and Dr. Lal PathLabs enables us to deliver cardiovascular diagnostics that can transform how heart disease is detected and managed in India,” Aimil Executive Director Dr. Mallika Kapur stated. “Our longstanding commitment to bringing medical technologies to the Indian healthcare ecosystem is strengthened by this collaboration, which we believe will make advanced molecular testing accessible to physicians and patients nationwide.”

The initial phase of this partnership has begun and is focused on integrating and promoting the test within Dr. Lal PathLabs’ laboratory and clinical network, ensuring alignment with Indian clinical and regulatory protocols. Once established, efforts will be focused on ramping up commercial rollout, which is expected this year.

“We are pleased to collaborate with Cardio Diagnostics and Aimil to bring PrecisionCHD to our network,” Dr. Lal PathLabs CEO Shankha Banerjee commented. “This partnership aligns with our mission to be the leader in providing patients, cardiologists and physicians with the most advanced and reliable diagnostic solutions. By integrating molecular-level detection of coronary heart disease into our services, we can help cardiologists and physicians identify disease earlier and support more effective, personalized treatment strategies.”

This expansion and collaboration underscore Cardio Diagnostics’ commitment to advancing precision medicine globally and addressing the urgent need for early detection and better management of heart disease in one of the world’s most populous regions.

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (core technology) for cardiovascular disease.

Aimil was founded in 1932, with a mission to bring leading edge technologies to India. With 14 sales and service offices across India, more than 1,000 employees, NABL-certified testing and calibration laboratories and manufacturing, R&D and software development capability, Aimil offers value-added distribution to overseas companies wanting to expand professionally in India.

Dr. Lal PathLabs Limited provides diagnostic and healthcare-related services in India. Headquartered in Delhi NCR, the company operates clinical laboratories, collection centers, and pick-up points, catering to millions of patients annually. It specializes in pathology and radiology testing, leveraging cutting-edge technology and stringent quality controls to ensure precision in diagnostics.